88 Results for "

DNA damage response

" in MedChemExpress (MCE) Product Catalog:
Products (88)

88 Results for "DNA damage response" in MCE Product Catalog:

Cat. No.: HY-145289
CAS No.: 3032101-64-4
Target:  

Apoptosis

Research Areas:  

Cancer

Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .
loading...
    loading...
Cat. No.: HY-P70212
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: GADD45B; Growth Arrest And DNA-damage-Inducible Beta; Prev. MYD118; DKFZP566B133; GADD45BETA; Growth Arrest And DNA-damage-Inducible, Beta; Growth Arrest And DNA damage-Inducible Protein GADD45 Beta; Myeloid Differentiation Primary response; Myeloid Diffe
Species:  
Human
Source:  
E. coli
loading...
    loading...
Cat. No.: HY-L264
1,544 compounds

DNA damage response (DDR) is a fundamental mechanism for maintaining genomic stability. When DNA damage occurs, such as single- or double-strand breaks or replication fork stalling, cells rely on key proteins including ATM, ATR, PARP, and DNA-PK to sense the damage and transmit signals, thereby regulating DNA repair, cell-cycle arrest, and cell death. Inhibition of specific DNA repair or checkpoint pathways can prevent tumor cells from effectively repairing accumulated DNA damage, ultimately leading to tumor cell death.

MCE DNA Damage Repair Inhibitor Library contains 1,544 compounds, focusing on key nodes involved in DNA damage response and DNA repair. The library covers multiple DNA repair and cell-cycle checkpoint pathways, providing a systematic compound screening tool for research on precision oncology, synthetic lethality, drug resistance mechanisms, and chemo- or radiosensitization.

Cat. No.: HY-P705526
Purity:  ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: PPP1R15A; Myeloid Differentiation Primary response Protein MyD116 Homolog; Protein Phosphatase 1 Regulatory Subunit 15A; Protein Phosphatase 1, Regulatory (Inhibitor) Subunit 15A; GADD34; Growth Arrest And DNA-damage-Inducible 34; Growth Arrest And DNA Da
Species:  
Human
Source:  
E. coli
loading...
    loading...
Cat. No.: HY-13567A
CAS No.: 1374784-02-7
Synonyms: SDX-105 hydrate
Research Areas:  

Metabolic Disease

Bendamustine hydrochloride hydrate (SDX-105 hydrate), a purine analogue, is a DNA cross-linking agent. Bendamustine hydrochloride hydrate activates DNA-damage stress response and apoptosis. Bendamustine hydrochloride hydrate has potent alkylating, anticancer and antimetabolite properties .
loading...
    loading...
Cat. No.: HY-180357
CAS No.: 1383995-51-4
Graviquinone is a Chk1 inhibitor. Graviquinone exhibits potent cytotoxicity against various cancer cell lines. Graviquinone possesses the characteristics of bypassing ABCB1-mediated multidrug resistance, selectively damaging cancer cell DNA, and regulating the DNA damage response. Graviquinone can also enhance cytotoxicity by increasing ROS levels in cancer cells. Graviquinone can be used for cancer research .
loading...
    loading...
Cat. No.: HY-189272
Research Areas:  

Cancer

ATR-IN-33 is an ATR kinase inhibitor (IC50 = 9.67 nM). ATR-IN-33 induces apoptosis, exacerbates DNA damage, and causes G1 phase cell cycle arrest by blocking CHK1 phosphorylation and DNA damage response signaling. ATR-IN-33 exhibits selective cytotoxicity against AML cell lines and can be used for research on acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-126258
CAS No.: 1458674-25-3
Research Areas:  

Infection

IMP-1700 is a potent DNA damage potentiator and antibacterial agent. IMP-1700 inhibits the bacterial SOS response to DNA damage. IMP-1700 potently sensitizes MRSA to Ciprofloxacin (HY-B0356) with an EC50 of 5.9 nM. IMP-1700 inhibits the growth of E. coli K-12 BW25113, S. aureus SH1000 and MRSA USA300 JE2 .
loading...
    loading...
Cat. No.: HY-182748
Research Areas:  

Cancer

NL-26 is a Topoisomerase I inhibitor. NL-26 stabilizes the covalent Topoisomerase I (Topo I)-DNA complex, prevents DNA religation and triggers the DNA damage response. NL-26 induces G2/M cell cycle arrest and apoptosis in cancer cells. NL-26 can be used for the research of colorectal cancer .
loading...
    loading...
Cat. No.: HY-171171
CAS No.: 2649242-85-1
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

NERx 329 is a replication protein A (RPA) inhibitor with an IC50 of 4.9 μM. NERx 329 blocks the interaction between RPA and single-stranded DNA, and induces functional RPA depletion, loss of single-stranded DNA gap protection, chromosome fragmentation and cell death. NERx 329 inhibits the DNA damage response signaling pathway, exhibits broad single-agent anticancer activity, and enhances the activity of DNA-damaging agents. NERx 329 can be used in research related to brca1-deficient breast cancer, non-small cell lung cancer, and brca1-deficient ovarian cancer .
loading...
    loading...
Cat. No.: HY-181786
CAS No.: 3104731-13-4
Target:  

ATM/ATR

Research Areas:  

Cancer

ATM-IN-13 (A36) is an orally active, selective ATM kinase inhibitor with a human IC50 of 0.3 nM. ATM-IN-13 blocks the ATM-mediated DNA double-strand break repair signaling pathway, reduces the phosphorylation levels of ATM and p53, and inhibits ATM-dependent DNA damage response. ATM-IN-13 can be used in the research of colorectal cancer .
loading...
    loading...
Cat. No.: HY-179585
Target:  

Apoptosis

Research Areas:  

Cancer

DD-CIP2 is a DNA damage and apoptosis inducer. DD-CIP2 demonstrates effective anti-proliferative activity against multiple cancer cell. DD-CIP2 modulates the DNA damage response pathway, triggering robust DNA damage, cell cycle arrest, and apoptosis in vitro. DD-CIP2 demonstrates significant anti-tumor efficacy in vivo at well-tolerated doses, without substantial toxicity. DD-CIP2 exhibits superior cytotoxic potency against a broad panel of blood-and solid-tumor-derived cancer cell lines independent of their BRCA1/2 status. DD-CIP2 can be used for small-cell lung cancer (SCLC) and non small-cell lung cancer (NSCLC) research .
loading...
    loading...
Cat. No.: HY-W585945
CAS No.: 56524-77-7
Research Areas:  

Inflammation/Immunology

Mono N-Desmethyl Disperse Polyester Dark Blue is a bioreductive agent that is activated under hypoxic conditions. Once inside a cell, it is reduced to its active form, which generates reactive oxygen species that can damage cellular components, including DNA. This damage can lead to cell death, particularly in hypoxic cancer cells that are already under stress. It has also been shown to inhibit the activity of hypoxia-inducible factor 1 (HIF-1) , which is a key regulator of the cellular response to hypoxia.
loading...
    loading...
Cat. No.: HY-182926
Research Areas:  

Cancer

Topoisomerase I/II-IN-9 is a topoisomerase I/II inhibitor (IC50<10 μM) and a DNA damage inducer. Topoisomerase I/II-IN-9 blocks the interaction between the enzyme and DNA by binding to the DNA-binding pocket of the enzyme. Topoisomerase I/II-IN-9 activates the cGAS-STING pathway and promotes the accumulation of cytoplasmic double-stranded DNA. This further drives the production of type I interferons, CCL5, CXCL10 and interferon-stimulated genes, and induces anti-tumor immune responses in vivo. Topoisomerase I/II-IN-9 can be applied to the research of related diseases such as triple-negative breast cancer, colorectal cancer and gastric cancer .
loading...
    loading...
Cat. No.: HY-189009
CAS No.: 3112500-81-6
Target:  

DNA/RNA Synthesis PAK

Research Areas:  

Cancer

WC-2 is an ATP-competitive covalent WRN helicase inhibitor with IC50 values of 252 nM and 250 nM. WC-2 binds covalently to Cys727 of WRN helicase and maintains conformational complementarity with this protein. WC-2 induces p21 transcription as part of the DNA damage response, and selectively reduces the viability of MSI-H cancer cells. WC-2 can be used in the research of MSI-H tumors .
loading...
    loading...
Cat. No.: HY-188120
AZD5335 is an ADC targeting FRα, with an IC50 of 10.6 nM against human FRα. AZD5335 specifically binds to FRα, mediates internalization and trafficking to lysosomal compartments, while delivering a topoisomerase I inhibitor payload that traps TOP1-DNA cleavage complexes. AZD5335 induces DNA damage response via the ATR, ATM, Chk1 and Chk2 signaling pathways, and increases the levels of phosphorylated KAP1, phosphorylated RPA, phosphorylated γH2AX, as well as PARP cleavage. AZD5335 exhibits bystander cytotoxicity against FRα-negative cells co-cultured with FRα-expressing cells. AZD5335 induces potent and durable responses and complete regression in ovarian cancer models, including models with low FRα expression and models resistant to Elahere, with enhanced efficacy when combined with Carboplatin, Bevacizumab or poly (ADP-ribose) polymerase inhibitors. AZD5335 can be used for ovarian cancer research .
loading...
    loading...
Cat. No.: HY-119578
CAS No.: 72963-72-5
Target:  

Cytochrome P450

Research Areas:  

Cancer

Imiprothrin is an inducer that induces CYP1A2 and metallothionein 1a, with significant genotoxicity and cytotoxicity. In rat hepatocytes, Imiprothrin initiates detoxification responses by triggering the overexpression of these two genes. Imiprothrin induces chromosomal aberrations and micronucleus formation in rat bone marrow cells, and causes DNA damage in hepatocytes. Imiprothrin triggers oxidative stress in rats, leading to lipid peroxidation, excessive reactive oxygen species production and redox imbalance, which in turn impairs liver and kidney functions and causes tissue damage. Imiprothrin inhibits weight gain in mice, and even causes high mortality in female mice at high doses. However, it shows no carcinogenicity in rat experiments; among relevant indicators, aspartate aminotransferase and total protein are identified as sensitive toxicity biomarkers .
loading...
    loading...
Cat. No.: HY-L244
761 compounds

In this era of rapid advancement in gene-editing technology, the CRISPR-Cas system, with its powerful programmability, is leading a transformation in life sciences research. It enables efficient and precise targeted modification of an organism's genome, providing a robust tool for studying gene function, treating genetic diseases, and improving crop varieties. However, bottlenecks such as insufficient editing efficiency, low homologous directed repair efficiency, and potential off-target risks remain major challenges in achieving precise genetic modifications and developing gene therapies.

To overcome these limitations, the MCE High-Efficiency Gene Editing Compound Library systematically includes 761 small molecules that are known or have the potential to enhance gene-editing efficiency. These compounds work by targeting and modulating the DNA damage repair network, mechanistically inhibiting non-homologous end joining, promoting homologous directed repair, or regulating chromatin states and cellular responses, thereby significantly optimizing editing outcomes. This library is suitable for developing "CRISPR-small molecule" combination therapy strategies, improving gene-editing efficiency, and providing a powerful tool for in-depth research into the mechanisms of DNA damage repair in gene editing.

Cat. No.: HY-109566R
CAS No.: 2089288-03-7
Synonyms: AZD1390 (Standard)
Elrelesertib (Standard) (AZD1390 (Standard)) is the analytical standard of Elrelesertib (AZD1390) (HY-109566). This product is intended for research and analytical applications. Elrelesertib (AZD1390) is an orally active, brain-penetrant ATM kinase inhibitor with IC50 values of 0.78 nM. Elrelesertib blocks ATM-dependent DNA damage response, inhibits ATM autophosphorylation and downstream Chk2, Rad50 phosphorylation, and accumulates at DNA breaks. Elrelesertib acts as a radiosensitizer, induces apoptosis, genomic instability, G2-M cell cycle arrest, ROS elevation, and mitochondrial membrane potential alteration. Elrelesertib has low efflux liability against P-gp and BCRP. Elrelesertib can be used for the research of central nervous system malignancies, glioblastoma multiforme, glioma, lung cancer brain metastases, and breast cancer .
loading...
    loading...
Cat. No.: HY-182586
CAS No.: 19198-75-5
Target:  

Fungal Bcl-2 Family

Research Areas:  

Infection

Decyl gallate is an antifungal (fungal) agent. Decyl gallate downregulates the expression of the pro-apoptotic (apoptosis) protein Bak, upregulates the expression of the anti-apoptotic protein Bcl-2, and inhibits DNA damage. Decyl gallate disrupts ALG12-mediated N-glycosylation, overactivates the UPR pathway, and simultaneously reduces fungal cell wall enzyme activity, chitin levels, mitochondrial activity, budding ability, cell viability, and host cell adhesion capacity. Decyl gallate reduces inflammatory responses induced by fungal infection and disrupts fungal membrane structure. Decyl gallate can be used in studies related to paracoccidioidomycosis and invasive fungal infections .
loading...
    loading...